The CDMO’s North Carolina facility has successfully completed an FDA inspection thereby validating its quality systems and commercial readiness to reinforce its position as a leader in complex topical and transdermal drug manufacturing.

In a market where investor confidence is tied to de-risked programs, the proven ability to solve complex manufacturing challenges, and established regulatory strength, the choice of a CDMO partner has never been more critical, remarks Ryan Lake from Lifecore Biomedical.

Insilico Medicine has entered a multi‑year R&D collaboration with Servier to discover and develop novel AI‑designed oncology therapies. The deal will combine Insilico’s Pharma.AI platform with Servier’s global oncology development and commercialization capabilities.

The first oral GLP-1 for weight loss treatment has been launched in the U.S. by Novo Nordisk, with pricing starting at USD 149 per month and availability at over 70,000 pharmacies in the country.

For Jeremie Trochu from Ardena, therapeutic selectivity, regional manufacturing resilience, and operational connectivity will prove to be critical themes for the industry over the coming months.

Ahead of the 2026 J.P. Morgan Healthcare Conference, Julien Meissonnier, Independent Director for Prolific Machines, breaks down the transitional phase of today’s market, highlighting the unsustainability of de-risking strategies in the long term.

For Megha Sinha from Kamet Consulting Group, industry conversations around key topics are shifting, as companies seek to gain the greatest operational benefits from AI and find ways to improve supply chain resilience without causing chaos.

The PRISM project has the potential to offer a fundamental shift to the way that regulatory bodies and industry collaborate and interact, according to Frits Stulp from Implement Consulting Group.

According to Maria Andreasen from FUJIFILM Biotechnologies, there will be three operational priorities that will separate bio/pharmaceutical leaders from the rest of the industry in 2026.

In this exclusive preview to J.P. Morgan Healthcare Conference 2026, Elliott Berger highlights his thoughts of promising therapeutic modalities and explains why regional manufacturing is no longer optional for biopharma companies seeking long-term resilience.

Facing mounting cost pressures and the logistical challenges of scaling next-generation therapies, biopharma innovators are pivoting towards strategic, integrated outsourcing models, remarks Tom Sellig from Adare Pharma Solutions.

Sweden’s Nanexa has entered a licensing and option deal with Moderna, granting access to its PharmaShell drug delivery platform to develop long-acting versions of Moderna’s mRNA-based therapies.

As chronic diseases rise globally, the bio/pharma industry is pivoting toward increasingly complex molecules that demand more sophisticated delivery strategies, which must be considered early on in development.

The raised funds, totaling USD 40 million, will be used to accelerate the company’s growth and to advance its robotic platform, Constellation, which enables flexible, scalable cell therapy manufacturing.

To strengthen its European presence and enhance high-impact event experiences for life science clients worldwide, ITA Group has acquired C2events, a UK-based event management agency specializing in healthcare and pharmaceutical conferences.

A new RSV A-strain challenge agent has been introduced by SGS to enhance CHIM studies and accelerate vaccine development. The breakthrough aims to generate more accurate, data-driven insights into RSV infection and immune response.

A collaboration between Rentschler Biopharma and Coriolis Pharma has been formed that will draw upon complementary scientific and technical expertise to provide end-to-end solutions for the biopharmaceutical value chain.

As demand for GLP-1 obesity drugs surges and affordability remains a competitive factor in the global weight-loss market, Eli Lilly slashes tirzepatide vial prices to boost access for self-pay patients.

Non-invasive drug delivery via pulmonary and nasal routes is increasingly in demand; however, while there has already been significant innovation within the sector, even more is required to meet future needs.

The regulator’s decision will provide a new clinical option for patients with early gastric and gastroesophageal cancers that can deliver a significant survival benefit versus chemotherapy alone.